Every material Form 8-K Elicio Therapeutics, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Elicio Therapeutics reported third quarter 2026 results on November 5, 2026, with a net loss of $8.0 million, down from $10.1 million a year earlier. The company said its cash and cash equivalents of $30.9 million as of September 30, 2026 will support operations into the second quarter of 2027, and it discussed Phase 2 AMPLIFY-7P results that did not meet the primary disease-free survival endpoint in the intent-to-treat population.
Net loss was $8.0 million, or $0.30 per share, versus $10.1 million, or $0.60 per share, in the third quarter of 2025.
R&D expense was $4.9 million versus $5.0 million; G&A expense rose to $3.6 million from $3.0 million.
Cash and cash equivalents were $30.9 million at September 30, 2026, with an expected runway into the second quarter of 2027.
AMPLIFY-7P missed its primary DFS endpoint in the intent-to-treat population; pre-specified subgroup analyses showed risk reductions of 49% and 43% in ctDNA-negative and ctDNA-positive patients.
Elicio Therapeutics has set November 12, 2026 as the date of its 2026 annual meeting of stockholders. Because the meeting date moves by more than 30 days from the anniversary of its last annual meeting, the company set September 24, 2026 as the deadline for stockholder proposals and director nominations.
Annual meeting date set for November 12, 2026; exact time, location and voting matters to be detailed in the proxy statement
Deadline for Rule 14a-8 stockholder proposals and bylaw notices of director nominations: September 24, 2026
Universal proxy notices under Rule 14a-19 also due by September 24, 2026
Elicio Therapeutics reported a second-quarter 2026 net loss of $8.2 million, down from $10.6 million a year earlier, and said its Phase 2 AMPLIFY-7P trial of ELI-002 7P did not meet its primary endpoint. The company plans a Phase 1 combination study in metastatic pancreatic cancer, anticipated to start in Q4 2026, and says its cash will support operations into the first quarter of 2027.
Net loss for Q2 2026 was $8.2 million, or $0.43 per share, versus $10.6 million, or $0.66 per share, in Q2 2025.
Cash and cash equivalents were $23.5 million as of June 30, 2026; a July 2026 registered direct offering raised approximately $15.0 million gross.
The Phase 2 AMPLIFY-7P trial did not meet its primary endpoint; the company continues to evaluate pre-specified subgroups, including the R0 resected population.
The Phase 1 combination study is anticipated to begin in Q4 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Elicio Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →